Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TVI-Prostate-1
- Development stage
- Unknown
- Lead developer
- TVAX Biomedical
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous, Intradermal
01
Overview
TVI-Prostate-1 is an autologous T cell immunotherapy being developed by TVAX Biomedical for the treatment of prostate cancer. The therapy is based on the TVAX Immunotherapy platform, which employs a unique two-step approach to generate a robust anti-tumor immune response. First, the patient is sensitized to their own tumor antigens through a vaccination consisting of irradiated autologous tumor cells combined with an adjuvant (typically GM-CSF). Following this priming phase, T cells are harvested from the patient's blood, activated and expanded ex vivo to large numbers, and then re-infused into the patient. These 'educated' effector T cells are designed to specifically recognize and eliminate cancer cells throughout the body. The program is currently in Phase 2 clinical development.
- Other names
- Prostate-1Prostate1Prostate 1
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on TVI-Prostate-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TVI-Prostate-1.